Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.

Simcere Pharmaceutical Group Limited

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

Fada Medical is developing a novel drug diffusion technology to enhance the wear time and performance of a cannula for long-term insulin pump use in individuals with type 1 diabetes.

Fada Medical

Simcere Pharmaceutical Group engages in the research, development, production, and sale of pharmaceutical products, focusing on oncology and central nervous system therapies. Self-described as a major player in the pharmaceutical industry.

Metric
Company Name	Simcere Pharmaceutical Group Limited	AbbVie Inc.	CanSino Biologics Inc.	Fada Medical
Symbol	2.10K	ABBV	6.18K
MSH ID	COM:SIMCERE	COM:ABBVIE	COM:CANSINOTECH	COM:FADAMEDICAL
Market	STOCKS	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Drug Manufacturers - General	Drug Manufacturers - Specialty & Generic	Medical Devices
Country	CN	US	CN	IE
Stage
Employee Count	7.03K	50K	1.49K
Website	simcere.com	abbvie.com	cansinotech.com	fadamedical.com
LinkedIn			cansino-biotechnology-inc.
Founders

Metric
Market Cap	1.85B	296.91B	833.96M
Enterprise Value
Monthly Web Traffic		1.18M
Web Traffic Growth		0.51
Valuation
Raised Capital		15B

Metric
Revenue	908.88M	54.32B	49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	685.55M	45.54B	-61.04M
EBITDA	129.40M	18.10B	-203.86M
Operating Income	100.74M	17.43B	-236.92M
Net Income	98.31M	4.86B	-203.94M
EPS	0.04	2.75	-0.83
Diluted EPS	0.04	2.74	-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.77	0.72	0.14
Operating Profit Margin	0.11	0.27	-0.86
EBITDA Margin	0.14	0.33	-4.15
Net Profit Margin	0.45	0.11	-1.42
Return on Equity	0.39	0.57	-0.16
Return on Assets	0.25	0.04	-0.11
Return on Capital Employed	0.09	0.15	-0.08

2096

COM:SIMCERE

Simcere Pharmaceutical Group

Last Close

6.61

25/11 08:08

Market Cap

14.37B

Beta: -

Volume Today

2.21M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	13.45	46.58
P/B Ratio	1.34	25.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.47	6.36	20.35
EV Multiple	25.52	17.44	-3.00

Metric
Days Sales Outstanding		75.54	485.87
Days Payables Outstanding	195.23		170.20
Days Inventory Outstanding	188.86	102.41	251.49
Operating Cycle	380.95	181.71	815.83
Cash Conversion Cycle	285.62	179.57	770.86
Asset Turnover	0.61	0.40	0.07

Metric
Operating Cash Flow		22.84B	-124.92M
Free Cash Flow		22.06B	-208.89M
Cash Flow to Debt	1.09	0.38	-0.12
Operating Cash Flow/Sales	0.17	0.42	-0.43
Free Cash Flow Yield	0.03	0.08	-0.25

Metric
Cash & Equivalents	276.08M	12.81B	388.10M
Accounts Receivable		66M	36.58M
Inventory	84.53M	4.10B	48.53M
Goodwill	19.60M	32.29B
Debt to Capitalization	0.17	0.91	0.34
Debt to Assets	0.09	0.45	0.21
Current Ratio	2.35	0.96	2.24
Quick Ratio	1.93	0.83	2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.01
R&D to Revenue	0.30	0.14	1.04
SG&A to Revenue	0.07		0.34